Pfizer to acquire immuno-oncology company Trillium Therapeutics for $2.2bn
US pharma giant Pfizer has agreed to acquire Trillium Therapeutics, a publicly listed Canadian clinical stage immuno-oncology company, for $18.5 per share or $2.26 billion in an all-cash deal. The portfolio of Trillium Therapeutics has biologics that have been designed to boost the ability of patients’ innate immune systems for detecting and killing cancer cells. […]